129 related articles for article (PubMed ID: 8241995)
1. Radioiodination of a monoclonal antibody using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
Garg S; Garg PK; Zhao XG; Friedman HS; Bigner DD; Zalutsky MR
Nucl Med Biol; 1993 Oct; 20(7):835-42. PubMed ID: 8241995
[TBL] [Abstract][Full Text] [Related]
2. Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
Reist CJ; Archer GE; Wikstrand CJ; Bigner DD; Zalutsky MR
Cancer Res; 1997 Apr; 57(8):1510-5. PubMed ID: 9108453
[TBL] [Abstract][Full Text] [Related]
3. Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
Reist CJ; Garg PK; Alston KL; Bigner DD; Zalutsky MR
Cancer Res; 1996 Nov; 56(21):4970-7. PubMed ID: 8895752
[TBL] [Abstract][Full Text] [Related]
4. N-succinimidyl 5-(trialkylstannyl)-3-pyridinecarboxylates: a new class of reagents for protein radioiodination.
Garg S; Garg PK; Zalutsky MR
Bioconjug Chem; 1991; 2(1):50-6. PubMed ID: 1878411
[TBL] [Abstract][Full Text] [Related]
5. Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent.
Zalutsky MR; Archer GE; Garg PK; Batra SK; Bigner DD
Nucl Med Biol; 1996 May; 23(4):449-58. PubMed ID: 8832699
[TBL] [Abstract][Full Text] [Related]
6. Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR.
Foulon CF; Welsh PC; Bigner DD; Zalutsky MR
Nucl Med Biol; 2001 Oct; 28(7):769-77. PubMed ID: 11578897
[TBL] [Abstract][Full Text] [Related]
7. Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution.
Zalutsky MR; Xu FJ; Yu Y; Foulon CF; Zhao XG; Slade SK; Affleck DJ; Bast RC
Nucl Med Biol; 1999 Oct; 26(7):781-90. PubMed ID: 10628557
[TBL] [Abstract][Full Text] [Related]
8. Radioiodination of proteins using N-succinimidyl 4-hydroxy-3-iodobenzoate.
Vaidyanathan G; Affleck DJ; Zalutsky MR
Bioconjug Chem; 1993; 4(1):78-84. PubMed ID: 8431515
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent.
Shankar S; Vaidyanathan G; Affleck DJ; Peixoto K; Bigner DD; Zalutsky MR
Nucl Med Biol; 2004 Oct; 31(7):909-19. PubMed ID: 15464393
[TBL] [Abstract][Full Text] [Related]
10. Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate.
Vaidyanathan G; Affleck DJ; Bigner DD; Zalutsky MR
Nucl Med Biol; 2002 Jan; 29(1):1-11. PubMed ID: 11786270
[TBL] [Abstract][Full Text] [Related]
11. Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate.
Schuster JM; Garg PK; Bigner DD; Zalutsky MR
Cancer Res; 1991 Aug; 51(16):4164-9. PubMed ID: 1714341
[TBL] [Abstract][Full Text] [Related]
12. Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.
Shankar S; Vaidyanathan G; Kuan CT; Bigner DD; Zalutsky MR
Nucl Med Biol; 2006 Jan; 33(1):101-10. PubMed ID: 16459265
[TBL] [Abstract][Full Text] [Related]
13. Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate.
Reist CJ; Foulon CF; Alston K; Bigner DD; Zalutsky MR
Nucl Med Biol; 1999 May; 26(4):405-11. PubMed ID: 10382844
[TBL] [Abstract][Full Text] [Related]
14. Radioiodination of antibodies via N-succinimidyl 2,4-dimethoxy-3-(trialkylstannyl)benzoates.
Vaidyanathan G; Zalutsky MR
Bioconjug Chem; 1990; 1(6):387-93. PubMed ID: 2099187
[TBL] [Abstract][Full Text] [Related]
15. Method for radioiodination of proteins using N-succinimidyl 3-hydroxy-4-iodobenzoate.
Vaidyanathan G; Affleck DJ; Zalutsky MR
Bioconjug Chem; 1997; 8(5):724-9. PubMed ID: 9327137
[TBL] [Abstract][Full Text] [Related]
16. Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate.
Zalutsky MR; Noska MA; Colapinto EV; Garg PK; Bigner DD
Cancer Res; 1989 Oct; 49(20):5543-9. PubMed ID: 2477144
[TBL] [Abstract][Full Text] [Related]
17. Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer.
Wilbur DS; Hadley SW; Hylarides MD; Abrams PG; Beaumier PA; Morgan AC; Reno JM; Fritzberg AR
J Nucl Med; 1989 Feb; 30(2):216-26. PubMed ID: 2738650
[TBL] [Abstract][Full Text] [Related]
18. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
Kuan CT; Reist CJ; Foulon CF; Lorimer IA; Archer G; Pegram CN; Pastan I; Zalutsky MR; Bigner DD
Clin Cancer Res; 1999 Jun; 5(6):1539-49. PubMed ID: 10389943
[TBL] [Abstract][Full Text] [Related]
19. Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6.
Lee Y; Bullard DE; Humphrey PA; Colapinto EV; Friedman HS; Zalutsky MR; Coleman RE; Bigner DD
Cancer Res; 1988 May; 48(10):2904-10. PubMed ID: 2452014
[TBL] [Abstract][Full Text] [Related]
20. N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate: synthesis and potential utility for the radioiodination of monoclonal antibodies.
Garg PK; Garg S; Zalutsky MR
Nucl Med Biol; 1993 May; 20(4):379-87. PubMed ID: 8504279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
